Adjuvant Chemotherapy for Testicular Cancer

To the Editor: The report by Williams et al. (Dec. 3 issue)* draws conclusions based on a prospective randomized trial comparing immediate brief-course chemotherapy with delayed chemotherapy in patients with pathological Stage II nonseminomatous germ-cell tumors of the testis. The data are important, but can be misinterpreted. The authors state that “a brief course of cisplatin-based adjuvant chemotherapy will almost always prevent relapse.” However, their strictly defined study population limits the applicability of this conclusion. The median number of positive nodes in the two arms of the study were three and two, respectively. Only five patients in one arm and.